DEF: Tharimmune Seeks Shareholder Approval for Capital Flexibility

Tharimmune, Inc. calls a special meeting to vote on increasing authorized common stock, expanding its equity incentive plan, and authorizing future non-public offerings to support growth and capital needs.

Summary

• Stockholders will vote on a proposal to increase the total number of authorized common stock from 250,000,000 shares to a range between 500,000,000 and 1,000,000,000 shares.
• A proposal to amend the Tharimmune, Inc. Amended and Restated 2023 Omnibus Equity Incentive Plan (the 2023 Plan) will be voted on, increasing the shares reserved for issuance from 792,602 to 2,000,000 shares.
• Stockholders will also consider authorizing the issuance of securities in one or more non-public offerings, not exceeding $350,000,000 in cash or 350,000,000 shares, with a maximum discount of 90% to market price, within 90 days of the Special Meeting.
• As of the Record Date (August 26, 2025), 5,903,437 shares of common stock were outstanding.
• The Board of Directors recommends a 'FOR' vote on all three proposals.

Sentiment

Score: 6

Explanation: The proposals are necessary enabling actions for the company's operational flexibility and growth, including attracting talent and raising capital. However, they also carry significant potential for shareholder dilution, which is a notable negative. The overall sentiment is cautiously positive, acknowledging the strategic necessity while highlighting the dilutive impact.

Positives

• Provides the Board with flexibility for future financings, investment opportunities, and acquisitions.
• Enables the company to continue offering equity-based compensation, which is crucial for attracting, motivating, and retaining highly qualified talent.
• Aligns the interests of employees and directors with those of shareholders through equity awards.
• Allows the company to respond quickly to capital market opportunities for raising additional funds.

Negatives

• The issuance of additional shares could dilute the voting rights of existing stockholders.
• Potential for dilution of earnings per share and book value per share for current stockholders.
• The increase in authorized common stock could serve as an anti-takeover measure, making it more difficult for other parties to gain control.
• The proposed increase in the 2023 Plan shares represents an additional potential equity dilution of approximately 10.6%.

Risks

• Significant dilution of voting rights, earnings per share, and book value per share for existing stockholders if additional shares are issued under the increased authorization or future offerings.
• The increase in authorized common stock could have an anti-takeover effect, potentially deterring or making more difficult a merger, tender offer, proxy contest, or extraordinary corporate transaction opposed by the company.
• Concentration of voting power in the hands of a few stockholders if a large block of shares is purchased by one or more investors in a non-public offering.

Future Outlook

The company anticipates raising additional capital through equity financings for working capital and general corporate purposes, pursuing investment opportunities and acquisitions, and continuing to use equity awards to attract and retain key talent. These proposals are designed to provide the necessary flexibility to achieve these strategic objectives.

Management Comments

• Our Board has determined that the Authorized Share Increase is in the best interests of the Company as the availability of additional authorized shares of common stock is required for several reasons including, but not limited to, the additional flexibility to issue common stock for a variety of general corporate purposes.
• We are seeking shareholder approval to amend our 2023 Plan to increase the number of shares of common stock available for issuance to 2,000,000 shares so that the Company can continue to provide equity-based compensation as approved by our Compensation Committee.
• We anticipate the additional shares requested under the amendment, plus the remaining shares that are available for issuance under the 2023 Plan, to be sufficient for a period of one year.
• We believe the stock reserved under the 2023 Plan will provide us with the platform needed for our continued growth, while managing program costs and share utilization levels within acceptable industry standards.

Industry Context

The company operates in a competitive business environment and talent market, particularly in the medical devices marketplace, where equity awards are a key component of competitive compensation packages. The significant working capital requirements noted suggest a need for ongoing capital raises, which is common in growth-stage or R&D-intensive industries.

Comparison to Industry Standards

• The company states its equity compensation program aims to manage program costs and share utilization levels within acceptable industry standards, but no specific comparable companies, projects, or results are provided for direct assessment.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for significant dilution of voting rights, earnings per share, and book value per share due to increased authorized shares and future offerings. However, the proposals aim to support company growth, which could benefit shareholders long-term.
• Employees & Directors: Enhanced ability to receive equity-based compensation, serving as an incentive for attraction, retention, and alignment with company performance.
• Potential Investors: Increased flexibility for the company to raise capital, potentially offering new investment opportunities.

Next Steps

• Hold the Special Meeting on October 9, 2025, for stockholder votes on the proposals.
• If approved, the Board will determine the exact size of the authorized share increase and file the Certificate of Amendment with the Delaware Secretary of State.
• If approved, the Board will proceed with the amendment to the 2023 Omnibus Equity Incentive Plan.
• If approved, the company may proceed with one or more non-public offerings within 90 days of the Special Meeting.
• File a Current Report on Form 8-K with the SEC within four business days after the Special Meeting to disclose voting results.

Key Dates

Recommendation

The proposals are enabling actions rather than direct performance indicators. While they provide necessary flexibility for future growth, capital raising, and talent retention, they also introduce significant potential for shareholder dilution. A 'hold' recommendation reflects the strategic necessity of these measures balanced against the inherent dilutive risks, suggesting investors monitor how these authorizations are utilized and the terms of any future capital raises.

Keywords

Tharimmune, THAR, SEC filing, proxy statement, special meeting, authorized shares, equity incentive plan, capital raise, non-public offering, stock dilution, corporate governance, Nasdaq rules, common stock, warrants, options